Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.61 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.61 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.54 |
| ▸ | CTSA | P10619 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941508 | 0.87 | MMP9 (0.65) | PLA2G4BMMP9MMP8MMP13SMN1; SMN2 | |
| SCHEMBL2939695 | 0.86 | MMP9 (0.67) | PLA2G4BMMP9MMP8MMP13SMN1; SMN2 | |
| SCHEMBL2949131 | 0.86 | MMP9 (0.67) | PLA2G4BMMP9MMP8MMP13SMN1; SMN2 | |
| SCHEMBL2948148 | 0.84 | FFAR1 (0.68) | MMP9MMP8MMP13SMN1; SMN2ALDH1A1 | |
| SCHEMBL9474072 | 0.83 | MMP9 (0.70) | PLA2G4BMMP9MMP8MMP13SMN1; SMN2 | |
| SCHEMBL15474084 | 0.81 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1PLA2G4BCTSAMMP9 | |
| SCHEMBL2946236 | 0.81 | FFAR1 (0.53) | PLA2G4BCTSAMMP9MMP8MMP13 | |
| SCHEMBL29299771 | 0.79 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1PLA2G4BSMPD1SMN1; SMN2 | |
| SCHEMBL28035866 | 0.79 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1PLA2G4BSMPD1SMN1; SMN2 | |
| SCHEMBL11605478 | 0.79 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1PLA2G4BSMPD1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | claimed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | claimed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176912-A1 | GPR40 AGONISTS | GPR119, GPR65, GPR55 | CYSLTR2 644/4885CYSLTR1 426/4885PLA2G4B 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.